Latest advances in pancreatic cancer healing

lleri/ June 2, 2019/ 2.1.- Cancer/ 0 comments

Next to the lung and colon, pancreatic cancer is one of the most aggressive cancers that are.

The pancreas is a vital organ, without which can not live because of their uniqueness in the body.

If it is blocked and the pancreatic juices do not occur, quickly ensues the death by not be able among other things neutralize with Na2CO3 HCl generated in the stomach to make normal digestion.

When a tumor in the pancreas, it expands much more easily because of the spongy nature of your fabric. In addition, a peculiarity which has cancer of the pancreas, (Adeno Carcinoma of Pancreas) is that he is created in a microenvironment very special in which 20% is the tumor itself and “80% of this comprises”stromal”, a layer dermoplástica which helps to grow the tumor and also l and isolated from the external environment which doesn’t penetrate cells”, which are responsible for attacking antigens (substances created by invaders or harmful cells to the body), with what immunotherapy is not applicable in this case.

What has been achieved has been to identify who is responsible for this cancer.

The enemy to block are two that are applicable drugs:

-The receiver of the epidermal growth factor, now mutated into the Adeno Carcinoma of lung, for which effective drugs have already developed to be mutated in the case of adeno carcinoma lung.

-Against the other factor in combination which is none other than the protein c-RAF, there are no drugs and inhibitors that has worked so far are highly toxic so to be able to neutralize the action of this molecule is one of the objectives.

Occurs here a very big challenge, since pancreatic cancer to be so devastating for having a rate very low survival, is expected to be the second type of cancer in the number of cases for the year 2030.

ADP (pancreatic ductal Adenocarcinoma) is one of the most widespread challenges to solve in the plane of cancer ailments. Being a 5% ailment, i.e. very low survival, it is anticipated that in 10 years is the second leading cause of death in cancer cases in the world being already the third in the United States.

The delay in diagnosis due to the lack of symptoms and the inefficacy of the treatments are sufficient causes to confirm these data.

The fact already described of the type of tissue surrounding the tumor and prevents the access of lymphocytes T by invalidating treatments with immunotherapy as well as the fact that 95% of these cases are initiated by mutations of oncogenes KRAS, for which have not yet been able to create fárm Harassment other than cytotoxic ones, which at most manage to prolong the patient’s life for a few weeks.

The fact already described of the type of tissue surrounding the tumor and prevents the access of lymphocytes T by invalidating treatments with immunotherapy as well as the fact that 95% of these cases are initiated by mutations of oncogenes KRAS, for which have not yet been able to create fárm Harassment other than cytotoxic ones, which at most manage to prolong the patient’s life for a few weeks.

However, when discovering the mechanism of propagation of this type of cancer, from the s mutations of the oncogene KRAS, but of all the kinases found involved in the transmission of signals of the oncogene KRAS (15 kinases), only 3 of them have a capacity Remarkably therapeutic is the aforementioned C-RAQF1, EGFR (Receptor of epidermal growth Factor) and CDK4.

The fact already described of the type of tissue surrounding the tumor and prevents the access of lymphocytes T by invalidating treatments with immunotherapy as well as the fact that 95% of these cases are initiated by mutations of oncogenes KRAS, for which have not yet been Able to create Fárm Harassment other than cytotoxic ones, which at most manage to prolong the Patient’s life for a few weeks.

However, when discovering the mechanism of propagation of this type of cancer, from the s mutations of the oncogene KRAS, but of all the kinases found involved in the transmission of signals of the oncogene KRAS (15 kinases), only 3 of them have a capacity Remarkably Therapeutic is the aforementioned C-RAQF1, EGFR (Receptor of epidermal growth Factor) and CDK4.

After several tests, it was found that the elimination of C-RAF1 and ECFR led to the complete regression of ADP in half of the mice that had been induced this ailment.

Now what is being studied is the possibility of increasing this percentage by eliminating also CDK4.

 Now the whole task is focused on the identification of these targets that are made resistant in tumors without affecting toxically, which is not going to be simple. It will also be necessary to design C-RAF1 inhibitors because for now there are only effective drugs against EGFR and those for C-RAF1 which focus on inhibiting kinase activity, avoid adherence to oncogene KRAS, avoid signaling oncogenic with C-RAF1 and also degrade it with drugs. The eminent Spanish oncologist Mariano Barbacid, shows us the path to be followed by blocking the activity of C-RAF1 in patients who have already developed ADP. This certainly will take more time than desired, but at least we know identified the enemy to beat.

Share this Post

Leave a Comment

Your email address will not be published. Required fields are marked *

*
*